Advances in the Delivery of Cancer Therapeutics: A Comprehensive Review

Jeswani, Gunjan; Paul, Swarnali Das; Jha, Arvind Kumar

doi:10.2174/1567201814666170726105219

Cited by 20 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It can be seen that neoadjuvant chemotherapy may be a risk factor for anastomotic leakage. It may affect the occurrence of anastomotic leakage by affecting the local tissue healing ability of the anastomosis and the supply of microcirculation blood [10,11]. However, at present, many centers have shown through research that whether neoadjuvant chemotherapy is performed has nothing to do with the risk of anastomotic leakage [12,13].…”

Section: Discussionmentioning

confidence: 99%

Influence of Neoadjuvant Chemotherapy on Anastomotic Complications and Long-Term Prognosis after Laparoscopic Radical Gastric Cancer Surgery

Chuanxu¹,

Yao²,

Mi³

et al. 2021

J Clin Case Stu

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Influence of Neoadjuvant Chemotherapy on Anastomotic Complications and Long-Term Prognosis after Laparoscopic Radical Gastric Cancer Surgery

Chuanxu¹,

Yao²,

Mi³

et al. 2021

J Clin Case Stu

View full text Add to dashboard Cite

show abstract

“…Chemotherapy, as one of the most extensively used practical methods in the clinic, has markedly enhanced the treatment outcomes of the majority categories of cancer, 1 which play a central role in improving the survival and quality of life for patients with cancer. 2 Nevertheless, the development of resistance to traditional chemotherapeutic agents and novel targeted drugs is almost inevitable, 3 and it has remained the leading cause of chemotherapeutic treatment failure and cancer-related mortality.…”

Section: ■ Introductionmentioning

confidence: 99%

A Lysosome-Targeting Self-Condensation Prodrug-Nanoplatform System for Addressing Drug Resistance of Cancer

et al. 2022

View full text Add to dashboard Cite

Lysosome-targeting self-assembling prodrugs had emerged as an attractive approach to overcome the acquisition of resistance to chemotherapeutics by inhibiting lysosomal sequestration. Taking advantage of lysosomal acidification induced intracellular hydrolytic condensation, we developed a lysosomaltargeting self-condensation prodrug-nanoplatform (LTSPN) system for overcoming lysosome-mediated drug resistance. Briefly, the designed hydroxycamptothecine (HCPT)-silane conjugates self-assembled into silane-based nanoparticles, which were taken up into lysosomes by tumor cells. Subsequently, the integrity of the lysosomal membrane was destructed because of the acid-triggered release of alcohol, wherein the nanoparticles self-condensed into silicon particles outside the lysosome through intracellular hydrolytic condensation. Significantly, the LTSPN system reduced the half-maximal inhibitory concentration (IC 50 ) of HCPT by approximately 4 times. Furthermore, the LTSPN system realized improved control of large established tumors and reduced regrowth of residual tumors in several drug-resistant tumor models. Our findings suggested that target destructing the integrity of the lysosomal membrane may improve the therapeutic effects of chemotherapeutics, providing a potent treatment strategy for malignancies.

show abstract

“…The hypoxic condition of the tumor microenvironment (TME) ( Robey et al, 2005 ), the modification of epigenetics ( Assaraf et al, 2019 ) and the influence of cancer stem cells ( Zhou et al, 2021 ). With the maturation of nanotechnology, several new therapeutic methods for cancer are progressively being available to the public ( Zaimy et al, 2017 ; Dadwal et al, 2018 ; Jeswani et al, 2018 ; Wang et al, 2021a ).…”

Section: Introductionmentioning

confidence: 99%

Extracellular vesicles derived from macrophages: Current applications and prospects in tumors

Lou

Feng²,

Luo³

et al. 2022

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Macrophages (Mφs) are significant innate immune cells that perform a variety of tasks in response to different pathogens or stimuli. They are widely engaged in the pathological processes of various diseases and can contribute to tumorigenesis, progression and metastasis by regulating the tumor microenvironment and cancer cells. They are also the basis of chemoresistance. In turn, the tumor microenvironment and the metabolism of cancer cells can limit the differentiation, polarization, mobilization and the ability of Mφs to initiate an effective anti-tumor response. Extracellular vesicles (EVs) are small vesicles released by live cells that serve as crucial mediators of intercellular cell communication as well as a potential promising drug carrier. A growing number of studies have demonstrated that Mφs-EVs are not only important mediators in the pathological processes of various diseases such as inflammatory disorders, fibrosis and cancer, but also show significant potential in immunological modulation, cancer therapy, infectious defense and tissue repair. These natural nanoparticles (NPs) derived from Mφs are believed to be pleiotropic, stable, biocompatible and low immunogenic, providing novel alternatives for cancer treatment. This review provides an update on the pathological and therapeutic roles of Mφs-EVs in cancer, as well as their potential clinical applications and prospects.

show abstract

Advances in the Delivery of Cancer Therapeutics: A Comprehensive Review

Cited by 20 publications

References 0 publications

Influence of Neoadjuvant Chemotherapy on Anastomotic Complications and Long-Term Prognosis after Laparoscopic Radical Gastric Cancer Surgery

Influence of Neoadjuvant Chemotherapy on Anastomotic Complications and Long-Term Prognosis after Laparoscopic Radical Gastric Cancer Surgery

A Lysosome-Targeting Self-Condensation Prodrug-Nanoplatform System for Addressing Drug Resistance of Cancer

Extracellular vesicles derived from macrophages: Current applications and prospects in tumors

Contact Info

Product

Resources

About